secwatch / observer
8-K filed May 1, 2026, 7:59 PM ET ticker ELOX CIK 0001035354
other material confidence high sentiment neutral materiality 0.60

Stockholders approve reverse split range, authorized share reduction, equity plan amendments via written consent

Eloxx Pharmaceuticals, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Eloxx Pharmaceuticals, Inc. shareholders approved Approve amendment to decrease authorized shares from 500,000,000 to 100,000,000 at the 2026-04-28 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2026-04-28
Exact text from the filing
(iv) approved an amendment to the Certificate of Incorporation to decrease the number of authorized shares of Common Stock from 500,000,000 to 100,000,000, such decrease to be effected at such time and date as determined by the Board at any time on or prior to the one-year anniversary of the Record Date as determined by the Board in its sole discretion.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Eloxx Pharmaceuticals, Inc. shareholders approved Approve amendment and restatement of 2018 Equity Incentive Plan at the 2026-04-28 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2026-04-28
Exact text from the filing
(ii) approved an amendment and restatement of the Original 2018 Plan, as amended by the First Amendment (the “Restated 2018 Plan”), in order to extend the period of time during which the Company may grant incentive stock options under the Restated 2018 Plan, further increase the ISO Limit, extend the evergreen provision and incorporate certain administrative and clarifying amendments;
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Eloxx Pharmaceuticals, Inc. shareholders approved Ratify first amendment to 2018 Equity Incentive Plan to increase shares to 20,000,000 and ISO limit to 30,000,000 at the 2026-04-28 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2026-04-28
Exact text from the filing
(i) ratified and approved the first amendment (“First Amendment”) to the Company’s 2018 Equity Incentive Plan (the “Original 2018 Plan”) to increase the number of shares of Common Stock available for issuance of awards thereunder to 20,000,000 shares and increase the incentive stock option share limit (the “ISO Limit”) to 30,000,000 shares, which the Board of Directors of the Company (the “Board”) had previously approved and adopted;
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Eloxx Pharmaceuticals, Inc. shareholders approved Approve reverse stock split of common stock at ratio between 1-for-2 and 1-for-20 at the 2026-04-28 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2026-04-28
Exact text from the filing
(iii) approved amendments to the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”) to effect a reverse stock split of the Company’s Common Stock at a ratio ranging from any whole number between 1-for-2 to 1-for-20, with the exact ratio to be determined at the sole discretion of the Board at any time on or prior to the one-year anniversary of the Record Date;
View on SEC.gov

224 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-201408
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.